Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection

Journal of Hepatology

Volumn 61, Issue 4, 2014, Pages 785-791

  Spradling, Philip R ^a   Bulkow, Lisa ^b   Teshale, Eyasu H ^a   Negus, Susan ^c   Homan, Chriss ^c   Simons, Brenna ^c   McMahon, Brian J ^b,c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^c ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

Author keywords

Aminotransferase levels; Hepatitis B; Immune active disease; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; COMORBIDITY; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; GENOTYPE; GROUPS BY AGE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; POPULATION; PREVALENCE; PRIORITY JOURNAL; STEATOSIS; YOUNG ADULT; BLOOD; DRINKING BEHAVIOR; GENETICS; HEPATITIS B, CHRONIC; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY; PATIENT ACUITY; REGISTER; RISK FACTOR; UNITED STATES;

ADULT; ALANINE TRANSAMINASE; ALASKA; ALCOHOL DRINKING; ANTIVIRAL AGENTS; COHORT STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT ACUITY; PREVALENCE; REGISTRIES; RISK FACTORS;

EID: 84926321964     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.05.045     Document Type: Article

References (25)

1. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45-S55.
2. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26: 628-638. http://dx.doi.org/10.1111/j.1440-1746.2011.06695.x.
3. Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis 2012; 16: 347-369.
4. Lok ASK, McMahon BJ. AASLD practice guidelines: chronic hepatitis B. Hepatology 2007; 45: 507-539.
5. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASK. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
6. Jafri SM, Lok AS. Antiviral therapy for chronic hepatitis B. Clin Liver Dis 2010; 14: 425-438.
7. Croagh CM, Bell SJ, Locarnini S, Desmond PV. Assessment of chronic hepatitis B: the importance of hepatitis B virus DNA testing. Intern Med J 2012; 42: 170-175.
8. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
9. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B; a 2012 update. Hepatol Int 2012. http://dx.doi.org/10.1007/s12072-012-9365-4.
10. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC. Serum activity of alanine aminotransferase as an indicator of health and disease. Hepatology 2007; 47: 1363-1370.
11. Pratt DS, Kaplan MM. Evaluation of abnormal liver enzyme results in asymptomatic patients. N Engl J Med 2000; 342: 1266-1271.
12. Ioannou GN, Boyco EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2001. Am J Gastroenterol 2006; 101: 76-82.
13. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960-967.
14. McMahon BJ, Schoenberg S, Bulkow L, Wainwright RB, Fitzgerald MA, Parkinson AJ, et al. Seroprevalence of hepatitis B viral markers in 52, 000 Alaska natives. Am J Epidemiol 1993; 138: 544-549.
15. McMahon BJ, Bulkow LR, Singleton RJ, Williams J, Snowball M, Homan C, et al. Elimination of hepatocellular carcinoma and acute hepatitis B in Children 25 years after a hepatitis B newborn and catch-up immunization program. Hepatology 2011; 54: 801-807.
16. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-1853.
17. Clark JM. The epidemiology of non-alcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: S5-S10.
18. Angulo P. Non-alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
19. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis on Northern Italy. Ann Intern Med 2000; 132: 112-117.
20. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
21. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998; 47: 1-39.
22. McMahon BJ, Hennessy TW, Christensen C, Bruden D, Sullivan DG, Homan C, et al. Epidemiology and risk factors for hepatitis C in Alaska natives. Hepatology 2004; 39: 325-332.
23. McMahon BJ, Bulkow L, Simons B, Zhang Y, Negus S, Homan C, et al. Population-Based study of hepatitis B "e" antigen negative persons with hepatitis B: prevalence immune active liver disease. Clin Gastroenterol Hepatol 2014; 12: 701-706.
24. Daniel S, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients. Gastroenterology 1999; 94: 3010-3014.
25. Lazo M, Selvin S, Clark JM. Clinical implications of short-term variability in liver function test results. Ann Intern Med 2008; 148: 348-352.